PanIN and CAF transitions in pancreatic carcinogenesis revealed with spatial data integration.
Visium
Xenium
imaging mass cytometry
machine learning
multi-omics
pancreatic adenocarcinoma
pancreatic intraepithelial neoplasia
spatial transcriptomics
transfer learning
Journal
Cell systems
ISSN: 2405-4720
Titre abrégé: Cell Syst
Pays: United States
ID NLM: 101656080
Informations de publication
Date de publication:
02 Aug 2024
02 Aug 2024
Historique:
received:
07
07
2023
revised:
06
02
2024
accepted:
08
07
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
8
8
2024
Statut:
aheadofprint
Résumé
This study introduces a new imaging, spatial transcriptomics (ST), and single-cell RNA-sequencing integration pipeline to characterize neoplastic cell state transitions during tumorigenesis. We applied a semi-supervised analysis pipeline to examine premalignant pancreatic intraepithelial neoplasias (PanINs) that can develop into pancreatic ductal adenocarcinoma (PDAC). Their strict diagnosis on formalin-fixed and paraffin-embedded (FFPE) samples limited the single-cell characterization of human PanINs within their microenvironment. We leverage whole transcriptome FFPE ST to enable the study of a rare cohort of matched low-grade (LG) and high-grade (HG) PanIN lesions to track progression and map cellular phenotypes relative to single-cell PDAC datasets. We demonstrate that cancer-associated fibroblasts (CAFs), including antigen-presenting CAFs, are located close to PanINs. We further observed a transition from CAF-related inflammatory signaling to cellular proliferation during PanIN progression. We validate these findings with single-cell high-dimensional imaging proteomics and transcriptomics technologies. Altogether, our semi-supervised learning framework for spatial multi-omics has broad applicability across cancer types to decipher the spatiotemporal dynamics of carcinogenesis.
Identifiants
pubmed: 39116880
pii: S2405-4712(24)00183-2
doi: 10.1016/j.cels.2024.07.001
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests E.M.J. reports other support from Abmeta; personal fees from Genocea; personal fees from Achilles; personal fees from DragonFly; personal fees from Candel Therapeutics; other support from the Parker Institute; grants and other support from Lustgarten; personal fees from Carta; grants and other support from Genentech; grants and other support from AstraZeneca; personal fees from NextCure; and grants and other support from Break Through Cancer outside of the submitted work. E.J.F. is on the Scientific Advisory Board of Viosera Therapeutics/Resistance Bio and is a consultant to Mestag Therapeutics. W.J.H. reports patent royalties from Rodeo/Amgen and speaking/travel honoraria from Exelixis and Standard BioTools.